Table 4:

Patient factors associated with erlotinib treatment (multivariate analysis) – Patients who did not have genetic test

	Model 1 – Without clinical variables		Model 2 – With clinical variables included
	OR (CI)	P-value	OR (CI)	P-value
SES Variables
Low income	0.82 (0.69, 0.97)	0.024 *	0.86 (0.72, 1.02)	0.0896
High-poverty location	1.05 (0.9, 1.24)	0.5348	1.06 (0.9, 1.25)	0.5066
Demographic and Clinical Characteristics
Female	1.50 (1.29, 1.75)	<.0001 *	1.45 (1.24, 1.7)	<.0001 *
Black (vs. white)	0.52 (0.31, 0.85)	0.0093 *	0.58 (0.35, 0.97)	0.0382 *
Asian (vs. white)	2.34 (1.45, 3.78)	0.0005 *	2.45 (1.49, 4.02)	0.0004 *
Hispanic (vs. white)	0.83 (0.36, 1.93)	0.6679	0.64 (0.26, 1.58)	0.3304
Other/unknown (vs. white)	1.80 (0.97, 3.35)	0.0636	1.85 (0.97, 3.53)	0.0602
Urban location	1.01 (0.8, 1.28)	0.943	1.02 (0.81, 1.3)	0.8552
Diagnosis year	0.90 (0.8, 1.01)	0.0758	0.89 (0.79, 1.01)	0.0735
Adenocarcinoma	-	-	1.14 (0.98, 1.33)	0.0989
Under 75 at diagnosis	-	-	0.91 (0.78, 1.06)	0.2072
Charlson index 3+ (vs. 0)	-	-	0.79 (0.58, 1.09)	0.1489
Charlson index 2 (vs. 0)	-	-	0.97 (0.7, 1.34)	0.8541
Charlson index 1 (vs. 0)	-	-	1.05 (0.82, 1.36)	0.6808
Diagnosis Year Interaction Variables
Low income	1.02 (0.92, 1.02)	0.5302	1.03 (0.97, 1.09)	0.4011
High-poverty location	0.97 (0.96, 1.08)	0.2537	0.97 (0.92, 1.03)	0.3238
Female	0.95 (0.91, 1)	0.8955	0.95 (0.9, 1)	0.0439 *
Black (vs. white)	0.96 (0.81, 1.13)	0.5901	0.94 (0.8, 1.12)	0.4964
Asian (vs. white)	1.04 (0.9, 1.22)	0.5723	1.02 (0.87, 1.19)	0.835
Hispanic (vs. white)	1.04 (0.8, 1.35)	0.7945	1.11 (0.84, 1.46)	0.4608
Other/unknown (vs. white)	0.99 (0.8, 1.21)	0.8963	0.96 (0.78, 1.19)	0.7338
Urban location	1.01 (0.93, 1.09)	0.8955	1.00 (0.92, 1.08)	0.9808
Adenocarcinoma	-	-	1.05 (0.99, 1.1)	0.09
Under 75 at diagnosis	-	-	1.05 (0.99, 1.1)	0.0824
Charlson index 3+ (vs. 0)	-	-	0.99 (0.89, 1.09)	0.7842
Charlson index 2 (vs. 0)	-	-	0.97 (0.87, 1.07)	0.5177
Charlson index 1 (vs. 0)	-	-	1.00 (0.92, 1.08)	0.9733

^*= Significant at the 0.05 level